Although deregulation of miR-146a has been reported in type 2 diabetes repeatedly, the direction of deregulation events (up or down) remained to be inconsistent in literatures. Therefore, in this study we performed a metaanalysis on the possible association between miR-146a expression levels and type 2 diabetes. A systematic literature searching of PubMed, ISI Web of Science and Google Scholar was performed up to the end of September 2016. Finally, a total of 12 studies including 344 diabetic patients and 316 controls were selected for meta-analysis. All statistical analysis was performed using the metafor package with R software. Moreover, publication bias was assessed by Egger's and sensitivity analysis was applied on the meta-analysis. The results are presented as log10 odds ratios (logORs), 95% confidence intervals (CI) with relevant P values. The results revealed that miR-146a was downregulated in type 2 diabetes cases compared with normal subjects (P=0.01, logOR:-4.76, 95% CI:-8.41, -1.11). Furthermore, sub-group analysis showed that the association between miR146a expression levels and type 2 diabetes in whole blood (P<0.001) and PBMCs (P<0.001) samples were significant. However, this association was not significant in the serum (P=0.67) and plasma (P=0.90) samples.
compared with control subjects (15) (16) (17) (18) 23) .
Nonetheless, in contrast to these results, it has been reported that miR-146a serum level was significantly upregulated in newly diagnosed T2D patients compared to individuals with normal glucose tolerance (22) . The inconsistency may be due to the use of small sample size, different profiling methods and sample sources. Hence, to obtain a robust comprehension, here we aimed at pooling studies of miR-146a expression in T2D
samples compared with healthy controls, and then performing a meta-analysis while considering different confounding variables.
Methods

Search strategy
A Systematic literature search using PubMed, ISI Web of Science and Google Scholar were performed for relevant articles from 1993 to September 2016 and the language was restricted to English. To find eligible articles, a combination of the following key words was used: "miR-146a", "expression", "profiling", "type 2 diabetes", "circulating", "plasma", "serum", and "blood". In additon, to identify additional eligible studies, we scanned the reference lists of reviews and publications selected for inclusion in this paper.
Selection criteria and publication quality assessment
Studies were eligible if they met the following criteria: (1) had miRNAs expression profiling design, (2) compared patients with diabetes and healthy controls, (3) with information on cut-off criteria (P-value or fold-change) for differentially expressed genes, (4) studied human circulatory miRNAs (whole blood, PBMC, serum, plasma and platelet), and (5) reported total number of samples in both patient and control groups. We excluded review articles and studies that determined miRNAs 
Data extraction and quality assessment
The required data were retrieved by two independent investigators from the full-text eligible articles and supplementary materials. 
Statistical analysis
All analyses were performed using the metafor package with R statistical software 3.1. Metaanalysis was performed as described elsewhere (24) . To assess the statistical significance, we made 2x2 contingency table for miR-146a based on the number of dysregulation events in both type 2 diabetes and non-diabetic control subjects. The outcomes are presented as log10 odds ratios (logORs), with their 95% confidence intervals. The miRNAs upregulation was indicated when a significant logOR higher than one was obtained from cases to controls. on contrary, miRNAs downregulation was indicated with a significant logOR higher than one, whenever controls were compared to cases. 
Results
The characteristics of included studies
After titles and abstracts initial screening, 10 Finally, a total of 12 studies/sub-studies including 344 T2D patients and 316 normal samples were selected for meta-analysis (Table 1) .
Meta-analysis of miR-146a expression in T2D
We applied a random-effects model for the meta-analysis, since I 2 (total heterogeneity/ total variability) was as 90.15%. Overall, meta-analysis revealed that miR-14a was downregulated in T2D Studies have shown that miR-146a interacts directly with interleukin-1 receptor-associated kinase 1 (IRAK1)/TNF receptor-associated factor 6 (TRAF6), thus attenuating the inflammatory cytokines production in macrophages (26, 27) . It has been reported that patients suffering from T2D have significantly decreased levels of miR-146a (15, 21 ).
yet, in contrast to these findings, an increased expression of this miRNA has also been previously reported (5, 14) .
Further, the subgroup analysis by sample type showed that the association between miR-146a expression level and T2D was significant in PBMCs and whole blood samples, whereas it was not significant for serum and plasma samples. conduct meta-analysis, our study differs in several aspects regarding this study. First, we considered only miR-146a which is presented in circulatory sources (serum, plasma and PBMCs). Second we only included studies with human subjects.
Considering such criteria makes our study more accurate in determining the potential role of miR146a as non-invasive biomarker for T2D and its complications.
Even though we tried to perform a welldesigned and robust meta-analysis, the present study may suffer from some limitations. First, the existing bias in publishing of reports has significant result. Second, in the subgroup analysis using sample types, the number of studies in each group was relatively small. Third, methodological limitation in miRNAs expression meta-analysis analyzed all studies with non-significant results.
Four, because our meta-analysis did not estimate the contribution of other risk factors related to T2D
and also the stage of disease, these variables may have influenced the result of our study and partially explain the discrepancies in the involved casecontrol studies.
In conclusion, our finding suggest that miR146a downregulation could be associated with T2D susceptibility. Furthermore, this result suggests that miR-146a can be considered as a potent marker to predict the clinical outcome of diabetes. This association needs to be confirmed through more clinical investigations with larger sample size and well characterized study populations.
